SCHEMBL6498946

SCHEMBL6498946

CC(C)(C)OC(=O)N1CCCC(OC(N)=O)C1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 1/20 0.51
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
ALDH1A1 P00352 1/20 0.50
MAPT P10636 1/20 0.50
EPHX1 P07099 1/20 0.46
ATM Q13315 1/20 0.45
PDE4B Q07343 1/20 0.45
CHEK2 O96017 1/20 0.45
USP2 O75604 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
PRMT5 O14744 1/20 0.43
WDR77 Q9BQA1 1/20 0.43
RECQL P46063 1/20 0.43
GPR119 Q8TDV5 1/20 0.42
PREP P48147 2/20 0.42
ABL1 P00519 1/20 0.42
RIN1 Q13671 1/20 0.42
PARP1 P09874 1/20 0.41
USP30 Q70CQ3 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6498939 1.00 HPGD (0.51) HPGDMEN1KMT2AALDH1A1MAPT
SCHEMBL9834172 1.00 HPGD (0.51) HPGDMEN1KMT2AALDH1A1MAPT
SCHEMBL10912935 0.91 HPGD (0.50) HPGDMAPTEPHX1ATMPDE4B
SCHEMBL21938019 0.91 HPGD (0.50) HPGDMAPTEPHX1ATMPDE4B
SCHEMBL9836659 0.91 HPGD (0.50) HPGDMAPTEPHX1ATMPDE4B
SCHEMBL24611623 0.87 HPGD (0.52) HPGDMEN1KMT2AALDH1A1MAPT
SCHEMBL3955730 0.87 HPGD (0.52) HPGDMEN1KMT2AALDH1A1MAPT
SCHEMBL4334069 0.87 HPGD (0.52) HPGDMEN1KMT2AALDH1A1MAPT
SCHEMBL29244745 0.87 HPGD (0.52) HPGDMEN1KMT2AALDH1A1MAPT
SCHEMBL22388002 0.85 HPGD (0.51) HPGDMEN1KMT2AALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050009843-A1 Medicine for inhibiting drug elimination pump TRINE PHARMACEUTICALS, INC. 2005-01-13 US disclosed
EP-1389463-A1 MEDICINE FOR INHIBITING DRUG ELIMINATION PUMP DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-02-18 EP disclosed
EP-0202048-B1 CARBAPENEM DERIVATIVES, THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM SANKYO COMPANY LIMITED (JP) 1991-10-30 EP disclosed
US-4771046-A ANTIBIOTICS SANKYO COMPANY, LIMITED (JP) 1988-09-13 US disclosed
EP-0202048-A1 Carbapenem derivatives, their preparation, and pharmaceutical compositions containing them SANKYO COMPANY LIMITED (JP) 1986-11-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050009843-A1 Medicine for inhibiting drug elimination pump ABCB11, ATP6AP1, HRH2 HPGD 735/4885MEN1 3567/4885KMT2A 3458/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.